Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Immatics Advances PRAME Oncology Pipeline for ESMO 2026
Research & Development Immatics Advances PRAME Oncology Pipeline for ESMO 2026

The pharmaceutical industry stands at a critical crossroads as the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid prepares to showcase breakthrough therapies that could finally bridge the gap between experimental biology and transformative patient care. Immatics N.V. is

Machine Learning LDL-C Estimation – Review
Tech & Innovation Machine Learning LDL-C Estimation – Review

For more than half a century, the medical community relied on a single mathematical shortcut to estimate the primary driver of heart disease, even as that shortcut failed millions of patients with complex metabolic profiles. Low-density lipoprotein cholesterol, or LDL-C, is the most frequently

Why Do Brain Diseases Only Target Specific Regions?
Research & Development Why Do Brain Diseases Only Target Specific Regions?

Ivan Kairatov is a leading biopharma expert whose work sits at the intersection of molecular innovation and neurodegenerative research. With years of experience in research and development, he has dedicated his career to untangling the complex web of protein interactions that govern brain health.

Safety Risks Rise for Compounded GLP-1s via Telehealth
Management & Regulatory Safety Risks Rise for Compounded GLP-1s via Telehealth

The explosive proliferation of GLP-1 receptor agonists has fundamentally altered the landscape of metabolic health, yet this therapeutic revolution is increasingly shadowed by the rise of loosely regulated digital distribution networks. While these medications provide life-changing benefits for

Next-Generation DMTA Systems – Review
Tech & Innovation Next-Generation DMTA Systems – Review

The persistent gap between the rapid generation of computational molecular designs and the slow physical validation of those molecules has become the primary bottleneck in contemporary therapeutic development. While artificial intelligence has succeeded in expanding the horizon of potential drug

Why Did GSK Scrap Its $2 Billion Chronic Cough Program?
Research & Development Why Did GSK Scrap Its $2 Billion Chronic Cough Program?

Ivan Kairatov has spent decades at the center of biopharmaceutical innovation, specializing in the high-stakes world of respiratory research and development. His expertise in dissecting the clinical and strategic failures of major drug candidates has made him a leading voice for investors and

Is Medical Device Packaging Truly Exempt Under EU PPWR?
Management & Regulatory Is Medical Device Packaging Truly Exempt Under EU PPWR?

The misconception that medical device packaging is entirely shielded from environmental mandates has recently collided with the rigorous realities of the European Union Packaging and Packaging Waste Regulation. While the healthcare sector often relies on exemptions to ensure sterility and patient

Delta Health Center Restores Healthcare Access in Rosedale
Management & Regulatory Delta Health Center Restores Healthcare Access in Rosedale

The sudden disappearance of a primary healthcare provider can leave a community in a state of quiet desperation, especially in regions where the nearest alternative is a highway away. Residents of Rosedale, Mississippi, recently navigated such a crisis when a six-month void in medical services

Polymer-Based Wireless Sensors Advance Health Monitoring
Tech & Innovation Polymer-Based Wireless Sensors Advance Health Monitoring

Healthcare systems worldwide are currently undergoing a massive transformation as they grapple with the complexities of managing an increasingly elderly population alongside a rising prevalence of chronic conditions like heart disease and diabetes. Traditional medical infrastructure often relies on

Ex-OpenAI Researcher Miles Wang to Launch $2B AI Biotech Startup
Tech & Innovation Ex-OpenAI Researcher Miles Wang to Launch $2B AI Biotech Startup

The pharmaceutical landscape is currently witnessing a tectonic shift as Miles Wang, a former prominent researcher at OpenAI, prepares to launch a specialized drug discovery venture that bridges the gap between generative artificial intelligence and complex biotechnology. This development marks a

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later